TWI738767B - 胺基酸衍生物之前藥 - Google Patents

胺基酸衍生物之前藥 Download PDF

Info

Publication number
TWI738767B
TWI738767B TW106112946A TW106112946A TWI738767B TW I738767 B TWI738767 B TW I738767B TW 106112946 A TW106112946 A TW 106112946A TW 106112946 A TW106112946 A TW 106112946A TW I738767 B TWI738767 B TW I738767B
Authority
TW
Taiwan
Prior art keywords
carbonyl
oxy
hexane
fluoro
amino
Prior art date
Application number
TW106112946A
Other languages
English (en)
Chinese (zh)
Other versions
TW201803842A (zh
Inventor
大嶽憲一
端早田
松田洋平
増田誠治
山內裕子
Original Assignee
日商大正製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商大正製藥股份有限公司 filed Critical 日商大正製藥股份有限公司
Publication of TW201803842A publication Critical patent/TW201803842A/zh
Application granted granted Critical
Publication of TWI738767B publication Critical patent/TWI738767B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/48—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing ten carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
TW106112946A 2016-04-18 2017-04-18 胺基酸衍生物之前藥 TWI738767B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016-083147 2016-04-18
JP2016083147 2016-04-18

Publications (2)

Publication Number Publication Date
TW201803842A TW201803842A (zh) 2018-02-01
TWI738767B true TWI738767B (zh) 2021-09-11

Family

ID=58737797

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106112946A TWI738767B (zh) 2016-04-18 2017-04-18 胺基酸衍生物之前藥

Country Status (29)

Country Link
US (2) US10464884B2 (enExample)
EP (1) EP3445743B1 (enExample)
JP (2) JP7045321B2 (enExample)
KR (1) KR102444718B1 (enExample)
CN (1) CN109071418B (enExample)
AU (1) AU2017254266B2 (enExample)
BR (1) BR112018069959B1 (enExample)
CA (1) CA3019097C (enExample)
CY (1) CY1124574T1 (enExample)
DK (1) DK3445743T3 (enExample)
ES (1) ES2886442T3 (enExample)
HR (1) HRP20211277T1 (enExample)
HU (1) HUE056046T2 (enExample)
IL (1) IL262233B (enExample)
LT (1) LT3445743T (enExample)
MX (1) MX379567B (enExample)
MY (1) MY195208A (enExample)
NZ (1) NZ747061A (enExample)
PH (1) PH12018502211A1 (enExample)
PL (1) PL3445743T3 (enExample)
PT (1) PT3445743T (enExample)
RS (1) RS62515B1 (enExample)
RU (1) RU2739318C2 (enExample)
SG (2) SG11201808387PA (enExample)
SI (1) SI3445743T1 (enExample)
SM (1) SMT202100601T1 (enExample)
TW (1) TWI738767B (enExample)
WO (1) WO2017183734A1 (enExample)
ZA (1) ZA201806444B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2886442T3 (es) * 2016-04-18 2021-12-20 Taisho Pharmaceutical Co Ltd Profármaco de derivado de aminoácido
JP7314494B2 (ja) * 2017-10-17 2023-07-26 大正製薬株式会社 アミノ酸誘導体のプロドラッグを含有する医薬
JP7436385B2 (ja) * 2018-04-24 2024-02-21 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド Ｈｉｖ成熟阻害活性を有する化合物
CN109180712B (zh) * 2018-08-08 2020-12-25 南京医科大学 一类2-茨醇的芳基硼酸酯衍生物及其应用
CN108948077B (zh) * 2018-08-09 2020-10-13 东华理工大学 一种α-磷酰化的α-氨基酸酯类化合物及其合成方法
WO2022114135A1 (ja) * 2020-11-26 2022-06-02 大正製薬株式会社 アミノ酸誘導体の結晶形及びその製造方法
CN112409443B (zh) * 2021-01-25 2021-04-27 潍坊科技学院 一种脯氨酸茨醇衍生物及其制备方法和在制备治疗心脑血管类疾病的药物中的应用
CN114805104A (zh) * 2021-01-29 2022-07-29 南京宁丹新药技术有限公司 一类氨基水杨酸类衍生物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068041A1 (en) * 2010-11-18 2012-05-24 Eli Lilly And Company 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045898A1 (en) * 2001-11-23 2003-06-05 Eli Lilly And Company Prodrugs of excitatory amino acids
DK1459765T3 (da) * 2001-12-27 2008-10-06 Taisho Pharmaceutical Co Ltd 6-fluorbicyclo 3.1.0 hexan-derivater
ES2394175T3 (es) 2003-06-26 2013-01-23 Taisho Pharmaceutical Co., Ltd Derivado de éster 2-amino-biciclo[3.1.0]hexano-2, 6-dicarboxílico
EP2502903A4 (en) 2009-11-19 2013-04-17 Taisho Pharmaceutical Co Ltd METHOD FOR PRODUCING A 3-ALKOXY-2-AMINO-6-FLUORBICYCLO- [3.1.0-] HEXANE-2,6-DICARBOXYLIC ACID DERIVATIVE AND A INTERMEDIATE PRODUCT THEREOF
TWI520935B (zh) 2010-11-18 2016-02-11 美國禮來大藥廠 作為ｍＧｌｕＲ２／３拮抗劑之４－經取代－３－苯基磺醯基甲基－雙環［３.１.０］己烷化合物
WO2013062680A1 (en) 2011-10-25 2013-05-02 Braincells, Inc. Novel compounds and compositions thereof for treating nervous system disorders
BR112014029478B1 (pt) 2012-06-01 2023-01-17 Taisho Pharmaceutical Co., Ltd Compostos, fármacos de aminoácido contendo flúor e uso destes
US20150119345A1 (en) 2013-10-29 2015-04-30 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of gastrointestinal infections
ES2886442T3 (es) * 2016-04-18 2021-12-20 Taisho Pharmaceutical Co Ltd Profármaco de derivado de aminoácido

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068041A1 (en) * 2010-11-18 2012-05-24 Eli Lilly And Company 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AkitoYasuhara et al., "Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (): A potent and orally active group II mGluR antagonist with antidepressant-like potential", Bioorganic & Medicinal Chemistry, Volume 14, Issue 12, 15 June 2006, Pages 4193-4207. *
AkitoYasuhara et al., "Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (MGS0039): A potent and orally active group II mGluR antagonist with antidepressant-like potential", Bioorganic & Medicinal Chemistry, Volume 14, Issue 12, 15 June 2006, Pages 4193-4207.

Also Published As

Publication number Publication date
RU2018140250A (ru) 2020-05-19
BR112018069959A2 (pt) 2019-02-05
CA3019097C (en) 2023-08-29
JP2019513755A (ja) 2019-05-30
ZA201806444B (en) 2020-01-29
CA3019097A1 (en) 2017-10-26
SG10202006019YA (en) 2020-08-28
MX2018012442A (es) 2019-02-21
MY195208A (en) 2023-01-11
US10464884B2 (en) 2019-11-05
BR112018069959B1 (pt) 2023-01-17
HUE056046T2 (hu) 2022-01-28
JP2021063095A (ja) 2021-04-22
CN109071418B (zh) 2022-03-18
AU2017254266B2 (en) 2021-03-11
RU2018140250A3 (enExample) 2020-06-23
CY1124574T1 (el) 2022-07-22
PT3445743T (pt) 2021-08-24
RS62515B1 (sr) 2021-11-30
AU2017254266A1 (en) 2018-10-25
ES2886442T3 (es) 2021-12-20
JP7045321B2 (ja) 2022-03-31
HRP20211277T1 (hr) 2021-11-12
EP3445743B1 (en) 2021-08-04
NZ747061A (en) 2021-07-30
KR20180134892A (ko) 2018-12-19
WO2017183734A1 (en) 2017-10-26
PL3445743T3 (pl) 2021-12-20
SI3445743T1 (sl) 2021-11-30
MX379567B (es) 2025-03-11
US20190047943A1 (en) 2019-02-14
TW201803842A (zh) 2018-02-01
LT3445743T (lt) 2021-09-27
CN109071418A (zh) 2018-12-21
KR102444718B1 (ko) 2022-09-16
DK3445743T3 (da) 2021-10-18
SG11201808387PA (en) 2018-10-30
PH12018502211A1 (en) 2019-10-21
US10689327B2 (en) 2020-06-23
IL262233B (en) 2021-09-30
EP3445743A1 (en) 2019-02-27
SMT202100601T1 (it) 2021-11-12
IL262233A (en) 2018-11-29
RU2739318C2 (ru) 2020-12-22
US20190337887A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
TWI738767B (zh) 胺基酸衍生物之前藥
CN114761412B (zh) 取代的大环化合物和相关治疗方法
EP3675848B1 (en) Spirocycle compounds and methods of making and using same
TWI659019B (zh) 吡唑醯胺衍生物
JP7042804B2 (ja) ピペラジンカルバメート、及びその製造と使用の方法
WO2023179629A1 (zh) 取代桥环类抑制剂及其制备方法和应用
IL259862A (en) Inhibitors of bruton's tyrosine kinase and methods of their use
CN107531696B (zh) 作为nmda受体调节剂的吡啶并嘧啶酮类及它们的用途
TW202530183A (zh) Ｒａｓ－ｐ１３ｋ抑制劑及其用途
AU2016232606A1 (en) Separation of enantiomers of 3-ethylbicyclo[3.2.0]hept-3-en-6-one
JP7314494B2 (ja) アミノ酸誘導体のプロドラッグを含有する医薬
EP4581036A1 (en) Egfr inhibitors and uses thereof
JP2018519354A (ja) ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
HK1260638B (zh) 氨基酸衍生物的前药
HK1260638A1 (en) Prodrug of amino acid derivative